Zebora Biotech Corp – Trademark Portfolio
Entity Type: 03
Zebora Biotech Corp has 4 U.S. trademark filings recorded with the United States Patent and Trademark Office (USPTO). Of these, 3 are successfully registered — a 75% registration rate. The portfolio includes marks such as ZEBORA. Filings span 4 Nice Classification classes, with the highest activity in Class 9 (Computers & Electronics) and Class 10 (Medical Apparatus). This trademark owner is based in Jamaica Plain, MA.
APT 306, 327 Centre Street
Jamaica Plain, MA 02130
Showing of trademarks Trademarks
Trademark Classifications
Zebora Biotech Corp's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Zebora Biotech Corp have?
Zebora Biotech Corp has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 cancelled.
What trademark classes does Zebora Biotech Corp file in?
Zebora Biotech Corp files trademarks across 4 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 31 (Natural Agricultural Products), Class 5 (Pharmaceuticals). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Zebora Biotech Corp's most well-known trademarks?
Zebora Biotech Corp's registered trademark portfolio includes well-known marks such as ZEBORA. These are among 3 currently registered trademarks in the portfolio.
What is Zebora Biotech Corp's trademark registration success rate?
Zebora Biotech Corp has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.